In a double-blind study of 48 patients with mixed hyperlipidemia, the human ANGPTL3/8 mAb reduced plasma TG levels by 70%, remnant cholesterol levels by 61%, LDL cholesterol levels by 36%, and APOB levels by 31%, while increasing HDL cholesterol levels by 26% (47). This evidence concerns the gene ANGPTL3 and Combined hyperlipidemia.